MSP008-22 / Godavari Biorefineries - LARVOL DELTA

Assessment of Safety, Tolerability and PK Profile of MSP008-22 in Patients With Advanced Solid Tumours (clinicaltrials.gov) - P1 | N=7 | Completed | Sponsor: Godavari Biorefineries Limited | Not yet recruiting ➔ Completed | N=27 ➔ 7 | Trial completion date: Jan 2023 ➔ Jan 2026 | Trial primary completion date: Dec 2022 ➔ Jan 2026

Enrollment change • First-in-human • Trial completion • Trial completion date • Trial primary completion date • Breast Cancer • Head and Neck Cancer • Ovarian Cancer • Prostate Cancer • Solid Tumor • Squamous Cell Carcinoma of Head and Neck • Triple Negative Breast Cancer

Phase One Clinical Trial to Assess the Safety, Tolerability and Pharmacokinetics of MSP008-22 in Healthy Adult Volunteers (clinicaltrials.gov) - P1 | N=64 | Completed | Sponsor: Godavari Biorefineries Limited | Trial completion date: Apr 2023 ➔ Nov 2025 | Trial primary completion date: Jan 2023 ➔ Nov 2025 | Not yet recruiting ➔ Completed

Trial completion • Trial completion date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease

Godavari Biorefineries' patent for anticancer molecule validated in Spain, UK and EU (CNBC-TV18) - "Godavari Biorefineries on Monday (July 7) announced that its European patent for a novel anti-cancer molecule has been successfully validated in Spain, the United Kingdom, and as a unitary patent across multiple European Union member states....In a stock exchange filing, Godavari Biorefineries said that the patented molecule has demonstrated efficacy against both cancer cells and cancer stem cells and is being explored as a potential therapy for various cancers, including breast and prostate cancer."

Patent • Breast Cancer • Prostate Cancer

Sathgen Therapeutics announces completion of first cohort in phase 1 clinical trial with anti-cancer drug (ExpressPharma) - "Sathgen Therapeutics...announced the completion of the first cohort in a Phase 1 clinical trial with their first-in-class New Chemical Entity (NCE), MSP008-22....Sathgen aims to develop MSP008-22 for difficult-to-treat cancers, starting with triple negative breast cancer (TNBC) and prostate cancer as proof-of-principle. The lead molecule targets both the bulk cancer cells as well as the treatment-resistant population, making it an exciting prospect against various types of aggressive cancers. Moreover, this NCE did not present any adverse events in the first cohort."

Trial status • Breast Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • Triple Negative Breast Cancer

Phase One Clinical Trial to Assess the Safety, Tolerability and Pharmacokinetics of MSP008-22 in Healthy Adult Volunteers (clinicaltrials.gov) - P1 | N=72 | Not yet recruiting | Sponsor: Godavari Biorefineries Limited

New P1 trial • Infectious Disease • Novel Coronavirus Disease

Assessment of Safety, Tolerability and PK Profile of MSP008-22 in Patients With Advanced Solid Tumours (clinicaltrials.gov) - P1 | N=27 | Not yet recruiting | Sponsor: Godavari Biorefineries Limited

New P1 trial • Breast Cancer • Head and Neck Cancer • Oncology • Ovarian Cancer • Prostate Cancer • Solid Tumor • Squamous Cell Carcinoma of Head and Neck • Triple Negative Breast Cancer